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curve 0.76) than the Crusade score (area under the curve 0.67) with the
hemorrhagic events.
Conclusions: In routine clinical practice, bleeding is a relatively frequent
non-cardiac complication of contemporary therapy for ACS. These two scores
discriminate major bleeding risk. The MEHRAN score seems more correlated
to the real life of the Tunisian coronary patients.*
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Background: Pharmacodynamic studies have shown that persistently high
residual platelet reactivity (HRPP) is common in patients with diabetes in
spite of clopidogrel treatment. Even, a 600-mg clopidogrel loading dose is not
sufﬁcient to overcome this effect, especially in diabetic patients with ACS.
This can be explained by altered resorption, altered liver metabolism, or
altered platelet response. Recently, it was demonstrated that clopidogrel given
crushed provided faster absorption and greater rate of clopidogrel inactive
metabolite in healthy subjects. 
Objective: The hypothesis of the study was that 600 mg clopidogrel
loading dose (LD) administered crushed may provide more effective platelet
inhibition than an equal clopidogrel dose taken orally as whole tablets in
patients with type 2 diabetes mellitus presenting with ACS.
Methods: In a prospective, single-center, single-blind study, 30 (58.9±8.4
years; 17 males) ACS diabetic patients were randomized to either 600 mg crushed
clopidogrel (n=15) or whole tablets (n=15) follow by a maintenance dose of 150
mg, respectively. Pharmacodynamic assessment was performed by VerifyNow
P2Y12 system accumetrics at 24 h and 3 days post LD. High Residual platelet
reactivity (HRPR) was defined as platelet reactivity units (PRU) > 235.
Results: The baseline characteristics were no different in the two groups. We
noted no difference between the antiplatelet effect produced by 600 mg crushed
clopidogrel compared with whole tablets at both 24h (PRU=199.73±79.3 vs
216.9±70.1; p=0.53) and at 3 days (PRU=164.3±92.9 for crushed clopidogrel vs
160.5±73.5 for whole tablet; p=0, 9). HRPR rate also was similar in the two
groups, 40% (p=1) at 24h and diminished significantly in both groups at 3 days to
20% of patients (p<0,001).
Conclusions: Despite the small sample size, the present study demon-
strates that clopidogrel given crushed in diabetic ACS patients is as effective
as whole tablet
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The BioMatrix™ and BioMatrix Flex™ stent in real life: results of a
2,500-patient French registry 
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Background: The five years results of the LEADERS trial demonstrated
that the relative risk of MACE was 17% lower with BioMatrix Flex vs.
Cypher Select and the BES was also associated with a significant 74% reduc-
tion in definite VLST. BioMatrix Flex is superior to Cypher stent in
subgroups of patients at higher risk (High Syntax score, Patients with STEMI,
Bifurcation lesions). Are these good results confirmed in the “real word”?
Objectives: The purpose of the present observational study is to capture
the clinical events of patients receiving the CE marked BioMatrix™ and the
BioMatrix Flex™ stents.
Methods: Prospective, multi-center observational study conducted in 2537
all-comer consecutive patients with symptomatic CAD in 40 French centers.
The primary endpoint is the occurrence of major adverse cardiac and cere-
brovascular events (MACCE), defined as composite of cardiac death, myocar-
dial infarction (Q-wave and non-Q-wave), cerebrovascular events and
clinically indicated target vessel revascularization at 12 months. 
Results: Population consisted of 76% of males, mean age: 65.67± 11.2 yrs.
Indications were 32.80% stable angina, 32.85% ACS and 19.73% silent isch-
emia; 41.10% of patients had multivessel disease. Risk factors were: hyperten-
sion (64.80%), dyslipidemia ( 68.43%), diabetes I & II (34.63%), family
history (30.26%) and current smoker (22.68%). 
Procedural results: Patients had 1.12±0.32 procedures and mean number
of stents implanted per procedure was 1.11±0.36. Procedural success was
obtained in 99.47%.
In-hospital results: 16 patients (0.63%) experienced at least one MACCE
in hospital including 5 deaths (0.20%) 3 MI (0.12%), no emergency CABG,
9 repeat PCI (0.35%) and 4 (0.16%) stent thrombosis.
Conclusion: In a real-life, post market registry in France, the BioMatrix™
and BioMatrix Flex™ confirm the excellent outcome observed in the Leaders
trial, one year MACCE (primary endpoint) will be available at the moment of
the presentation.
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Purpose: Despite restoration of TIMI 3 flow in the infarct-related artery
during pPCI, about 30% of patients experience incomplete myocardial reper-
fusion due to microvascular obstruction. Incomplete ST-segment resolution
hours after PCI is associated with increased risk of major adverse events.
Immediate stenting (IS) could lead to increase distal embolization and micro-
vascular obstruction, altering myocardial perfusion. The aim of this study was
to compare delayed stenting (DS) with IS in pPCI. 
Methods: We prospectively collected data from 180 consecutive patients
admitted with STEMI of <12 h duration undergoing pPCI with indication of
stent implantation. The decision to perform IS (n=127) or DS (n=53) was left
to the operators. In the IS group, stent placement was done immediately
during pPCI; in the DS group, after restoration of TIMI 3 flow patients were
given antithrombotic therapy and had a stent implanted several days later. The
primary endpoint was ST-segment resolution (STR) measured on ECGs 1 h
after pPCI; secondary endpoints were postprocedure TIMI flow and in-
hospital culprit artery reocclusion rate. Propensity score were used in regres-
sion adjustment to reduce bias between groups. 
Results: 96.2% of the DS patients had second angiography 4.3±2 days
after the pPCI. A stent was implanted in all patients in the IS group vs 45.1%
in the DS group (p<0.001). 75% STR was found in 13.4% in the IS group vs
37.7% in the DS group (propensity-score-adjusted OR 3.7, 95%CI 1.5-8.8,
p=0.004). TIMI 3 flow restoration was obtained in 92.1% in the IS group vs
98.1% in the DS group at the end of the pPCI (OR=0.97, 95%CI 0.2-4.4). In
hospital documented infarct related artery reocclusion was 5.5% vs 1.9%
(OR=0.21, 95%CI 0.02-2.14).
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Conclusion: These data suggest that delayed stenting may be safe, associ-
ated with a low rate of stenting and improved myocardial reperfusion. Ran-
domized studies with longer follow-up are warranted to comfirm the benefit
of delayed stenting in pPCI.
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Preinfarction angina associated with a better prognosis after primary
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Aims: The clinical significance of ischemic chest pain before acute ST-
elevation myocardial infarction (STEMI) remains an interesting issue of
investigation particularly in the era of percutaneous coronary intervention
(PCI). This study aimed to assess the impact of angina prior to STEMI on
short-term clinical outcomes in patients with acute STEMI undergoing pri-
mary PCI.
Methods: Among a total of 346 consecutive patients with STEMI under-
going primary PCI, 131(37.9%) had episodes of angina within 24 hours of
STEMI (PA group) and the remaining 215 were free of anginal symptoms
(non-PA group). Clinical characteristics, angiographic and procedural features,
and in-hospital and 30-day outcomes were compared between the two groups.
Results: Patients with angina prior to STEMI had fewer totally or
nearly totally occluded infarct-related artery (TIMI flow grade 0 – 1) at
initial angiography (78,0% vs 86,7%, p =0,01), and achieved more TIMI
flow grade 3 after primary PCI (90,3% vs 84,9%, p=0,04). These were
associated with higher rates of overall procedural success (95.9% vs.
91.8%, P=0.02) and of complete ST-segment resolution at 90 minutes after
the procedure (51,7% vs 40,3%, p=0,001).During a 30-day clinical follow-
up, the left ventricular ejection fraction was significantly improved
(54,0±8,6% vs 49,1±9,7%, p=0,002) and the primary endpoint of major
adverse cardiac events was reduced but not significantly in the PA group
(7.2% vs. 12.7%, P=0.01).
Conclusion: Presence of angina prior to acute STEMI is associated with better
outcome at a 30-day clinical follow-up in patients undergoing primary PCI.
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Background: Primary percutaneous coronary intervention (primary PCI)
is the preferred reperfusion strategy in patients presenting ST segment eleva-
tion myocardial infarction (STEMI). However, despite restoration of epicar-
dial coronary flow, damage of the microvascular circulation caused by distal
embolization of thrombotic material during primary PCI occurs in a large pro-
portion of patients, and affects the quality of myocardial reperfusion. In clin-
ical practice, important controversies remain concerning the usefulness of the
manual thrombectomy to improve myocardial reperfusion.
Methods: 239 consecutive STEMI patients with an < 12 hours  onset of
symptoms, were enrolled in this  registry. Patients were divided into 2 groups
according to the strategy used by the operator: pts treated by manual throm-
bectomy before primary PCI (n=102) and those treated by conventional-PCI
(n=137). The primary outcome was the post procedural frequency of complete
(> 70%) resolution of ST segment elevation. The secondary outcome was a
composite of cardiac death, re infarction, target vessel revascularisation and
hospital admissions for heart failure. 
Results: Baseline characteristics of the patients were equivalent in the
two groups.A TIMI 3 flow was obtained in 97.7% in the thrombectomy
group and in 93.3% in the control group (p=0.11).A complete resolution of
ST segment elevation occurred in 51.4% of patients in the thrombectomy
group and in 35,6% of those in the conventional-PCI group (p=0.018).
Multivariate analysis identified the use of manual thrombectomy as an
independent predictor of the primary outcome (HR=2.08 IC 95% (1.01 to
4,26); p=0.046). The cumulative Kaplan-Meier estimate of the secondar
composite end point was not significantly different between the 2 cohorts
at 1, 3 years.
Conclusion: In STEMI patients, manual thrombectomy strategy  results in
better myocardial reperfusion as assessed by the percentage of ST segment
resolution. Whether this strategy could translate into better cardiovascular out-
come requires further confirmation in larger trials.
054
Does optical coherence tomography-guided angioplasty yield additio-
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Background: It is unclear whether optical coherence tomography (OCT)
can optimise percutaneous coronary intervention and stenting. We evaluated
whether OCT-guided angioplasty would provide useful clinical information
beyond that obtained by angiography, and if this would modify physician
behaviour & treatment choices.
Methods: Prospective study of patients(pts) undergoing coronary angiog-
raphy for ST and non-ST elevation myocardial infarction (STEMI, NSTEMI),
stable angina (SA) or silent ischemia (SI). In all pts, 1 OCT run was per-
formed (OCT-pre) after initial angiography (angio-pre); and a 2nd run after
angioplasty (OCT-post). We compared thrombus burden, calcifications &
plaque dissection between OCT-pre and angio-pre . After angioplasty, we
compared stent malapposition, suboptimal stent deployment or lesion
coverage, and edge dissection as identified by OCT-post vs post-angioplasty
fluoroscopy alone. 
Results: 69 pts were included (13 STEMI, 23 NSTEMI, 27 SA, 6 SI);
46% multivessel disease; 10% had atheroma without significant lesions.
Results are shown in the Table. OCT-pre and post-angioplasty revealed
significantly more procedural information than angiography alone. This
led to a change in treatment strategy in 35/69 (51%), namely thromboaspi-
ration in 2(2.9%), rotational atherectomy in 4 (5.8%), additional stenting
in 13 (18.8%), additional balloon inflation in 20 (29%), GPIIb/IIIa inhibi-
tors in 8/69 (11.6%). 
Conclusion: Our results indicate that OCT performed before and after
angioplasty provides useful information beyond that obtained by angiography
alone, and modifies treatment strategy in more than half of pts. It remains to
be determined whether this translates into improved outcomes in the longer
term.
Table. Results
OCT-pre Angio-pre P value
Thrombus 38% 18% 0.046
Calcifications 78% 24% <10-5
Plaque dissection or rupture 27% 8% 0.02
OCT-post Angio-post P value
Stent malapposition 56% 0% <10-5
Sub-optimal deployment 46% 27% 0.07
Sub-optimal coverage 21% 11% 0.29
Edge dissection 22% 6% 0.045
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Background: According to ESC guidelines, a P2Y12 inhibitor should be
instituted as early as possible when the diagnosis of non ST elevation- acute
coronary syndrome (NSTE-ACS) is made. However, Prasugrel is recom-
mended in P2Y12-inhibitor-naive patients with known coronary anatomy who
are proceeding to PCI. We sought to investigate the safety and efficacy of pre-
load with prasugrel in patients with NSTE-ACS at the time of diagnosis.
Methods and results: We conducted a multicentre longitudinal cohort
study including 200 consecutive patients with NSTE-ACS revascularized by
PCI and pre-treated with prasugrel between April 2010 and April 2012. All
patients were treated according to a common established protocol, that
included a loading dose of prasugrel at the time of diagnosis. Mean age of our
patients was 60±8,6 years and they mostly presented with NSTEMI (82,5%).
Intra-hospital complications were limited to a 6% bleeding risk (access-site
bleeding only). At the median follow-up of 374±24days, bleeding occurred in
overall 18,5% of patients (at a mean delay of 134days), composed by 15,5%
of BARC 1 haemorrhage, 2,5% of BARC 2 and 0.5% of BARC 3 (gastro-
intestinal bleeding). No fatal haemorrhagic complication occurred. On univar-
iate analysis, CRUSADE score, female gender and kidney failure were asso-
ciated with bleeding whereas diabetes and dyslipidaemia were protectors
against bleeding. We identified on multivariate analysis the diabetes as a pro-
tector factor (HR=0.08 [0.02-0.39]) and the female gender as a risk factor
(HR=8.30 [3.83-18]). On another hand, ischemic recurrences concerned 3% of
patients and were favoured by female gender (HR=14 [2.73-72]) and CRU-
SADE score ≥2 (HR=10.46 [1.34-82]). 
Conclusion: Preloading with prasugrel NSTE-ACS patients who will
undergo PCI is a safe and efficient option, with only 3% of significant
bleeding at 1 year and no fatal outcome. However, further studies are needed
in the setting of NSTE-ACS with medical treatment.
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Figure – Risk factors of bleeding in univariate analysis
